MAPS-Funded MDMA Therapy for PTSD Is Back at the FDA, Without a New Phase 3 Trial
MDMA assisted therapy for PTSD appears to be back in front of the FDA. Psychedelic Alpha reported on August 9 that Resilient Pharmaceuticals has resubmitted the application the agency declined two years ago. MAPS responded to that report the next day without independently confirming it. The detail that matters is not the resubmission. It is that the company is reportedly going back without a new phase 3 trial.
Whatever the FDA decides, the cost of running a monitored treatment room is negotiable now. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| What was reported | Psychedelic Alpha reported on August 9 that Resilient resubmitted its MDMA assisted therapy application. MAPS responded without confirming it independently |
| Who that is | Formerly MAPS Public Benefit Corporation, then Lykos Therapeutics, renamed Resilient in August 2025 |
| The 2024 rejection | The FDA declined approval and asked for more work on durability, safety characterization and bias |
| The gamble | The resubmission proceeds without a new phase 3 trial |
| The new variable | The FDA published final psychedelic trial guidance in July 2026, covering the same issues |
| What it is not | A resubmission is not acceptance and not approval. The agency decides first whether to review it |
Interested in MDMA Treatment? We hope the FDA is close to approving MDMA Therapy. Get on the waiting list now!
Three Names, One Application
The corporate history confuses people. It is worth setting out plainly. The applicant began as MAPS Public Benefit Corporation. It became Lykos Therapeutics in January 2024. It was renamed Resilient Pharmaceuticals in August 2025.
MAPS itself is a nonprofit. It no longer has an active role in the drug development program. It did initiate and fund the underlying research, which completed in 2022. That explains why MAPS communicates about the milestone while describing the filing at arm’s length.
What the FDA Said in 2024
The agency declined approval in August 2024 through a complete response letter. It recommended additional research in three areas. It wanted better evidence on durability of response. It wanted fuller safety characterization. It wanted steps to reduce the potential for bias.
That last item is the hard one. In psychedelic trials, patients generally know whether they received the drug. That functional unblinding makes it difficult to separate a treatment effect from expectation.
The Central Gamble
Rick Doblin, who founded MAPS, put the central fact plainly. Two years after the FDA rejected the initial application, he said, the new application is being submitted without a new phase 3 study. Supporters frame the argument this way. The core efficacy findings and adverse event reporting remain sound, even though blinding was imperfect. Doblin has not disputed that the original trials involved partial functional unblinding. His position is that the data were valid anyway.
That is a real argument. It is also close to the argument that did not carry in 2024. Whether it lands now depends on one thing. Does the agency read its own recommendations as satisfiable through analysis and added data, or does it want a new trial?
Be precise about status. Submitting an application is not the FDA accepting it for review. Neither is approval. The agency first decides whether the resubmission is complete enough to review. Then it sets a timeline.
The New Guidance Cuts Both Ways
One thing changed between the rejection and the resubmission. In July the FDA published its final guidance, Psychedelic Drugs: Considerations for Clinical Investigations. We covered its arrival in our look at the finalized trial guidance, and what it signals for clinics already delivering interventional care.
The guidance addresses trial design, safety characterization, long term follow up and therapist delivered interventions. Those are close to the exact issues the 2024 letter raised.
MAPS reads it favorably. The organization says the guidance reflects approaches it developed with the FDA across decades of scientific collaboration. If that is right, the published standard may sit closer to the applicant’s own methodology than the 2024 rejection suggested. The less comfortable reading also holds. A written standard is harder to argue around than an unwritten one. Guidance that names functional unblinding as a design problem does not obviously help an application whose weakness was functional unblinding.
Where MAPS Sits, and How to Read It
MAPS has been candid that it considers the original rejection unfair. Its public statement argued the agency moved the goalposts on blinding methodology. That shift came after the trials concluded and the application had been accepted.
That is an advocacy position. It comes from an organization that spent decades and considerable donor money on this research. It may also be correct. Readers can hold both ideas.
Rick Doblin has framed the stakes in human terms. Roughly 13 million Americans live with PTSD, and he argues each year of delay carries a cost measured in suicides. The urgency is genuine. It is not evidence about trial design.
Why Clinics Should Track This
An approval would be the first for a psychedelic assisted therapy in the United States. The delivery requirements are what should interest operators.
MDMA assisted therapy as studied involves long sessions with trained personnel present throughout. That is a staffing and space model, not a prescription pad. Practices already running monitored treatment rooms are the closest existing infrastructure. It is the same pattern we have tracked across psilocybin and intravenous psychedelic development.
The guidance section on therapist delivered interventions matters here too. How the agency treats the human component will shape who can deliver these treatments. It will also shape what delivery costs. Ismail Ali, a co executive director at MAPS, framed the field’s real questions the same way. Regardless of how any single application turns out, he said, what matters now is how therapists are trained and how patient safety and outcomes are maximized. That is a delivery problem, and delivery is where clinics live.
Demand is not the question. The VA is separately running its own MDMA work, which we covered when a new trial put the therapy back in the spotlight. The broader shift in PTSD care is underway regardless of this application, as we described in our look at how psychedelic therapy is changing PTSD treatment.
Whatever the FDA decides, the cost of running a monitored treatment room is negotiable now. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
What to Watch Next
Three markers will show where this is heading.
First, whether the FDA accepts the resubmission for review at all. That decision comes before any judgment on the science.
Second, whether an advisory committee is convened. The 2024 process included one. Its skepticism about the trial data was pointed.
Third, what the agency says about blinding. If it signals that functional unblinding can be handled analytically, the path opens for every psychedelic program. If it holds the line, the field is looking at expensive new trials across the board.
For now, treat this as a reported filing rather than a turning point. A rejected application has reportedly gone back with arguments rather than a new trial behind it. That is a meaningful bet. Neither the company nor the FDA has publicly confirmed the submission, and the agency has not said whether it will take it up.
